文献速递淋巴瘤

早期不利型经典型霍奇金淋巴瘤中9p24.1改变与PD-L1表达:GHSG NIVAHL试验分析

9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
PubMed 文献 · Br J Haematol · 2021-09-14

该研究分析德国霍奇金研究组NIVAHL试验中82例早期不利型经典型霍奇金淋巴瘤患者的基线活检,评估9p24.1拷贝数改变及PD-L1、MHC I/II类蛋白表达。所有标本的Hodgkin/Reed-Sternberg细胞均存在不同程度9p24.1改变,97%病例肿瘤细胞表达PD-L1,但9p24.1改变或PD-L1/MHC表达对基于抗PD-1的一线治疗早期应答无明显影响。

要点

  • 早期不利型cHL中9p24.1改变普遍存在但异质性高、范围小于晚期或复发难治病例。
  • 97%病例肿瘤细胞表达PD-L1,MHC-II在>50%HRS细胞中表达较MHC-I更常见。
  • 9p24.1改变及PD-L1/MHC表达未见对NIVAHL方案早期应答的明显影响。

核心结论

  • 早期不利型cHL中9p24.1改变和PD-L1表达普遍存在,但未显示对基于抗PD-1的一线治疗早期应答有明显影响。

研究设计与样本

  • 分析德国霍奇金研究组NIVAHL试验(NCT03004833)中82例早期不利型cHL患者的基线活检。

主要发现

  • 所有可评估标本的HRS细胞均存在一定程度9p24.1拷贝数改变,瘤内异质性高,改变范围总体小于晚期或复发难治cHL。
  • 除2例外(97%)肿瘤细胞表达PD-L1,表达量不一。
  • MHC-I在>50%HRS细胞中表达罕见,而MHC-II在>50%HRS细胞中表达更常见。
  • 9p24.1拷贝数改变或PD-L1、MHC-I/II表达对基于抗PD-1的NIVAHL一线治疗早期应答未见明显影响。

临床怎么用

  • 基线9p24.1状态和PD-L1/MHC表达暂不能用于筛选可能从抗PD-1一线治疗中获益的早期不利型cHL患者。

局限性

  • 需进一步研究评估扩展的潜在生物标志物组合,以优化抗PD-1一线治疗cHL的分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High programmed cell death 1 ligand 1 (PD-L1) protein expression and copy number alterations (CNAs) of the corresponding genomic locus 9p24.1 in Hodgkin- and Reed-Sternberg cells (HRSC) have been shown to be associated with favourable response to anti-PD-1 checkpoint inhibition in relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In the present study, we investigated baseline 9p24.1 status as well as PD-L1 and major histocompatibility complex (MHC) class I and II protein expression in 82 biopsies from patients with early stage unfavourable cHL treated with anti-PD-1-based first-line treatment in the German Hodgkin Study Group (GHSG) NIVAHL trial (ClinicalTrials.gov Identifier: NCT03004833). All evaluated specimens showed 9p24.1 CNA in HRSC to some extent, but with high intratumoral heterogeneity and an overall smaller range of alterations than reported in advanced-stage or r/r cHL. All but two cases (97%) showed PD-L1 expression by the tumour cells in variable amounts. While MHC-I was rarely expressed in >50% of HRSC, MHC-II expression in >50% of HRSC was found more frequently. No obvious impact of 9p24.1 CNA or PD-L1 and MHC-I/II expression on early response to the highly effective anti-PD-1-based NIVAHL first-line treatment was observed. Further studies evaluating an expanded panel of potential biomarkers are needed to optimally stratify anti-PD-1 first-line cHL treatment.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Gerhard-Hartmann E, Goergen H, Bröckelmann PJ, et al. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial. Br J Haematol. 2021. PMID: 34520052. doi:10.1111/bjh.17793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。